|1.||Wolchok, Jedd D: 11 articles (07/2015 - 12/2008)|
|2.||Allison, James P: 8 articles (08/2013 - 04/2003)|
|3.||Ribas, Antoni: 8 articles (07/2010 - 12/2005)|
|4.||Rosenberg, Steven A: 7 articles (07/2008 - 07/2003)|
|5.||Postow, Michael A: 6 articles (07/2015 - 07/2013)|
|6.||Hodi, F Stephen: 6 articles (07/2015 - 04/2003)|
|7.||Gomez-Navarro, Jesus: 6 articles (07/2010 - 12/2005)|
|8.||Yang, James C: 6 articles (02/2009 - 07/2003)|
|9.||Dranoff, Glenn: 5 articles (06/2012 - 04/2003)|
|10.||Sznol, Mario: 4 articles (07/2015 - 10/2011)|
|1.||Melanoma (Melanoma, Malignant)
01/01/2013 - "For example, blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) significantly improved median overall survival of melanoma patients. "
01/01/2014 - "Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma."
08/26/2013 - "Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. "
08/01/2009 - "What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?"
12/23/2008 - "Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell responses and induce durable clinical responses in patients with metastatic melanoma. "
12/01/2013 - "Cytotoxic T lymphocyte antigen 4 (CTLA-4) gene +49G>A polymorphism was implicated to be associated with risk of malignant bone tumors, but the finding was inconclusive owing to the limited sample of a single study. "
09/15/2011 - "Polymorphisms in the cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene have been implicated in susceptibility to cancer, but the many published studies have reported inconclusive results. "
01/01/2008 - "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade therapies have been evaluated in clinical trials and have shown promise as possible options for treating patients with cancer. "
08/01/2015 - "Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has achieved noteworthy benefit in multiple cancers by blocking immunoinhibitory signals and enabling patients to produce an effective antitumour response. "
06/01/2015 - "An overview of the preclinical and recent clinical trial data on key immuno-regulatory agents currently in development, including antibody targeting of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1) on T-lymphocytes and its principal ligand (PD-L1) on tumor cells as well as immune agonists (e.g., anti-CD40). "
03/01/2001 - "In the present study we searched for an association between multiple sclerosis (MS) and the gene encoding the cytotoxic T lymphocyte antigen 4 (CTLA4). "
11/01/2012 - "FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis."
12/01/2009 - "The polymorphisms of exon 1 (+49 A/G) and promoter regions (-1722 T/C, -1661 A/G and -318 C/T)of cytotoxic T lymphocyte antigen 4 (CTLA4) and also haplotypes constructed from mentioned loci were investigated amongst 153 Iranian patients with definite multiple sclerosis (MS) and 190 healthy controls. "
03/01/2007 - "We conducted a meta-analysis concerning the association of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) gene polymorphisms with the risk of developing multiple sclerosis (MS). "
07/01/2002 - "The association of multiple sclerosis (MS) with alleles A and G of the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene, a candidate gene for autoimmune disorders, was studied. "
04/15/2003 - "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients."
05/01/2014 - "In the first-line treatment of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte antigen 4, Hsp27, and p53 are novel targets in clinical trials. "
12/15/2010 - "In a preclinical study, we evaluated IL-15 combined with antibodies to block the negative immune regulators cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death ligand 1 (PD-L1) in a metastatic murine CT26 colon carcinoma model. "
|5.||Sarcoma (Soft Tissue Sarcoma)
01/01/2015 - "Cytotoxic T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms are implicated to be associated with susceptibility to bone sarcomas, but published studies have reported inconclusive results. "
01/01/2015 - "Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas."
12/01/2012 - "Recent clinical trials have reported improved survival for two novel agents; ipilimumab, a humanized, IgG1 monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and vemurafenib , a BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitor targeting an activating mutation in the serine-threonine-protein kinase BRAF gene. "
|5.||Immunoglobulin G (IgG)
|6.||Protein Kinases (Protein Kinase)
|5.||Drug Therapy (Chemotherapy)